Abstract

Since aggregates of the microtubule‐binding protein tau were found to be the main component of neurofibrillary tangles more than 30 years ago, their contribution to neurodegeneration in Alzheimer's disease (AD) and tauopathies has become well established. Recent work shows that both tau load and its distribution in the brain of AD patients correlate with cognitive decline more closely compared to amyloid plaque deposition. In addition, the amyloid cascade hypothesis has been recently challenged because of disappointing results of clinical trials designed to treat AD by reducing beta‐amyloid levels, thus fuelling a renewed interest in tau. There is now robust evidence to indicate that tau pathology can spread within the central nervous system via a prion‐like mechanism following a stereotypical pattern, which can be explained by the trans‐synaptic inter‐neuronal transfer of pathological tau. In the receiving neuron, tau has been shown to take multiple routes of internalisation, which are partially dependent on its conformation and aggregation status. Here, we review the emerging mechanisms proposed for the uptake of extracellular tau in neurons and the requirements for the propagation of its pathological conformers, addressing how they gain access to physiological tau monomers in the cytosol. Furthermore, we highlight some of the key mechanistic gaps of the field, which urgently need to be addressed to expand our understanding of tau propagation and lead to the identification of new therapeutic strategies for tauopathies.

Highlights

  • This study revealed that the total amount of PBS-soluble high molecular weight (HMW) tau was equivalent between Alzheimer's disease (AD) and healthy brain extracts, the level of phosphorylation was significantly higher at S199, S396, and S404 sites in AD brains (Takeda et al, 2015) (Table 1)

  • clathrin-mediated endocytosis (CME) has been shown to mediate uptake of recombinant monomeric 0N4R-P301S tau in HEK293 and SH-SY5Y cells by suppressing the activity of CME components, including FCHO and AP180, by expressing their dominant-negative forms; interestingly, this mechanism was not shared by recombinant aggregated 0N4R-P301S tau, which was found to undergo dynamin-dependent clathrin-independent endocytosis (CIE) (Falcon, Noad, McMahon, Randow, & Goedert, 2018)

  • Knockdown of Ext1/ Ext2 has been shown to inhibit uptake of recombinant monomeric and fibrillar 2N4R tau and of human tau oligomers extracted from both AD and dementia with Lewy bodies brains in HEK293 cells, primary cortical and hippocampal neurons as well as human induced pluripotent stem cell (iPSC) derived neurons (Holmes et al, 2013; Puangmalai et al, 2020; Rauch et al, 2018; Stopschinski et al, 2018)

Read more

Summary

Introduction

Dynamin-dependent internalisation of pathological tau was shown in neurons expressing HA-2N4RP301L after application of cell-secreted 2N4R-P301L aggregates (Calafate et al, 2016). CME has been shown to mediate uptake of recombinant monomeric 0N4R-P301S tau in HEK293 and SH-SY5Y cells by suppressing the activity of CME components, including FCHO and AP180, by expressing their dominant-negative forms; interestingly, this mechanism was not shared by recombinant aggregated 0N4R-P301S tau, which was found to undergo dynamin-dependent CIE (Falcon, Noad, McMahon, Randow, & Goedert, 2018).

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.